Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Bruxelles  >  Fagron    FAGR   BE0003874915

FAGRON (FAGR)
My previous session
Most popular
  Report  
Real-time Quote. Real-time CHI-X - 01/22 11:30:00 am
16.1 EUR   -0.62%
2018FAGRON NV : quaterly sales release
2018FAGRON NV : half-yearly earnings release
2018FAGRON NV : quaterly sales release
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Bruxelles
01/16/2019 01/17/2019 01/18/2019 01/21/2019 01/22/2019 Date
15.6(c) 15.87(c) 16.05(c) 16.2(c) 16.21 Last
39 574 76 170 169 560 106 531 75 498 Volume
-0.57% +1.73% +1.13% +0.93% +0.06% Change
More quotes
Financials (EUR)
Sales 2018 473 M
EBIT 2018 79,0 M
Net income 2018 49,0 M
Debt 2018 232 M
Yield 2018 0,65%
Sales 2019 521 M
EBIT 2019 95,2 M
Net income 2019 65,2 M
Debt 2019 178 M
Yield 2019 0,83%
P/E ratio 2018 23,60
P/E ratio 2019 17,75
EV / Sales2018 2,93x
EV / Sales2019 2,55x
Capitalization 1 153 M
More Financials
Company
Fagron specializes in the development, marketing and distribution of healthcare products and services intended for healthcare professionals and institutions. The group ensures the sale of pharmaceutical formulas and raw materials, provides third-party pharmaceutical compounding services to... 
Sector
Pharmaceuticals
Calendar
02/07Earnings Release
More about the company
Surperformance© ratings of Fagron
Trading Rating : Investor Rating :
More Ratings
Latest news on FAGRON
2018NUVO PHARMA : Pharmaceuticals Announces 2018 Third Quarter Results
AQ
2018FAGRON NV : Disclosure of received notification
GL
2018FAGRON : continues strong turnover growth of first semester in the third quarter..
AQ
2018FAGRON : continues strong turnover growth of first semester in the third quarter..
GL
2018FAGRON : 3rd quarter earnings
CO
2018FAGRON NV : quaterly sales release
2018FAGRON NV : - Disclosure of received notification
AQ
2018FAGRON NV : Disclosure of received notification
AQ
2018FAGRON NV : Disclosure of received notification
GL
2018FAGRON : Threshold crossings
CO
More news
Analyst Recommendations on FAGRON
More recommendations
Sector news : Pharmaceuticals - NEC
05:14pJOHNSON & JOHNSON : J&J, U.S. states settle hip implant claims for $120 million
RE
01:36pJOHNSON & JOHNSON : Expects Sales Growth to Slow -- Update
DJ
01:20pJOHNSON & JOHNSON : to Pay $120 Million to Settle Multi-State Hip Implant Claims
DJ
01:08pJOHNSON & JOHNSON : 2019 revenue forecast misses expectations
RE
09:12aGLAXOSMITHKLINE : GSK completes acquisition of -2-
DJ
More sector news : Pharmaceuticals - NEC
Chart FAGRON
Duration : Period :
Fagron Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FAGRON
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 18,3 €
Spread / Average Target 14%
Managers
NameTitle
Rafael Padilla Papaceit Chief Executive Officer & Director
Koen Hoffman Chairman
Karin de Jong Chief Financial Officer & Executive Director
Giulia van Waeyenberge Independent Director
Frank Jozef Paul Vlayen Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
FAGRON13.45%1 309
JOHNSON & JOHNSON1.27%350 508
PFIZER-2.57%246 674
NOVARTIS5.09%227 840
ROCHE HOLDING LTD.5.96%223 053
MERCK AND COMPANY-0.71%197 291